Moberg Pharma ABOMXSTO: MOB

New number of shares and votes in Moberg Pharma AB (publ)

· Issued by Moberg Pharma AB

Summary by 6ix AI

Moberg Pharma AB (publ), a Swedish pharmaceutical company, had 49,304,428 shares and 49,304,428 votes as of June 30, 2026. The increase comes from an issue of 592,361 class C shares, a separate share class that has since been converted into common shares.

Key details

  • The company repurchased the newly issued class C shares and converted them to common shares under a conversion clause in its articles of association. All shares are now common shares.
  • As of June 30, 2026, Moberg Pharma holds 2,123,652 of its own common shares, which it says are intended to cover its commitments under its incentive program.

6ix AI wrote this summary from the release below and checked it against the release.

STOCKHOLM, June 30th, 2026, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 48,712,067. The 832,213 newly issued shares are held by the company to secure its commitments under the incentive program.

As per June 30th, 2026, the total number of shares in Moberg Pharma AB (publ) amounts to 49,304,428. All shares are common shares. The total number of votes are 49,304,428. The increase in the number of shares and votes results from an issue of 592,361 class C shares. The newly issued class C shares have been repurchased and, by virtue of the conversion clause in the articles of association, converted to common shares. As per June 30th, 2026, the company holds 2,123,652 common shares. The shares are intended to ensure fulfilment of commitments under the incentive program.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: [email protected]
Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail: [email protected]

About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on June 30th, 2026, at 8:00 am CET.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 14 countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe, APAC, Canada and China. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

https://news.cision.com/moberg-pharma/r/new-number-of-shares-and-votes-in-moberg-pharma-ab--publ-,c4365608

https://mb.cision.com/Main/1662/4365608/4159852.pdf

(c) 2026 Cision. All rights reserved., source Press Releases - English

Moberg Pharma AB on 6ix

Earlier from Moberg Pharma

Later from Moberg Pharma

All Moberg Pharma news releases